Europe Influenza Market Research Report forecast 2017-2023
Summary - A new
market study, titled “Europe Influenza Market : Market Estimation, Dynamics,
Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to
2023” has been featured on Wise Guy Reports.
Europe Influenza Market
Influenza is an upper respiratory tract disease and is caused
by the influenza virus. Influenza virus is mainly three types namely Influenza
A, Influenza B, and Influenza C. Influenza is a communicable disease, spread
through a flu cough, droplets from the infected people, sneeze or talks. The
common symptoms occur in influenza patients are chills, cough, running nose,
sore throat, body aches, headache, fatigue, some cases people may have vomiting
and diarrhea. The complication of the disease may include ear infections,
bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to
congestive heart failure, and asthma. Influenza commonly occurs in geriatric
population and children with less than % years of age
The infection may be
confirmed by testing the sputum, nose, or throat for the virus. A number of
rapid tests are available however polymerase chain reaction that detects the
virus’s RNA is more accurate.
The Europe Influenza
market is growing at a significant CAGR due to increase in geriatric
population. Increase in vaccination awareness, rising investment by companies
in research and development activities, and increasing number of immunization
programs organized by the government are the major factors fuelling the growth
of Europe influenza market over the forecast period. The major market players
have great pipeline products, Initiatives by government bodies such as WHO to
ECDC to control and prevent influenza, technological advancements in diagnostic
tests also fuel the growth of Europe influenza market over the forecast period.
However, lack of required funding, limited opportunities for the production of
vaccines, and stringent regulatory policies for new product approvals might
hamper the growth of Europe Influenza market. Due to limitations in current
technologies, the lengthy production times (approximately seven months),
increasing prices of Influenza diagnostic kits, and difficulties in the storage
of inventory also hinder the Europe influenza market.
The Europe influenza
market is segmented on the basis of product type, distribution channel, and end
user
Based on drug class,
Europe influenza market is segmented into the following:
Anti-viral drugs
Zanamivir
Oseltamivir
Amantadine
Rimantadine
Others
Interferons
Vaccines
Trivalent
Quadrivalent
Based on route of
administration, Europe influenza market is segmented into the following:
Oral
Parenteral
Others
Based on end-user, Europe
influenza market is segmented into the following:
Hospital pharmacies
Retail pharmacies
Others
Several international
players in Europe are actively involved in the development of vaccines and
drugs for influenza treatment to increase its market share. Vaccines are
majorly preferred for the influenza treatment which is key revenue contributor
for the growth of Europe Influenza market share. Launching of new products,
technological innovations, and approvals from European Medical Agency for
various drugs might fuel the growth of Europe Influenza market. For instance,
in July 2016, Sanofi Pasteur MSD announced the approval of the latest addition
to its family of influenza vaccines in the UK. Similarly, during 2009, three
vaccines Celvapan, Pandemrix, and Focetria were authorized as the mock-up
vaccines and converted into the pandemic-influenza vaccines after the
identification of A/H1N11 flu strain. Similarly, two vaccines Humenza and
Arepanrix were authorized using the emergency procedure and contributed renewed
interest in the Europe influenza market.
Europe holds a dominant share
in the global influenza market. The largest share is attributed to rising
awareness regarding the influenza virus and disease, raising investment by
companies in research and development, and increasing number of immunization
programs organized by the government are some of the factors driving the Europe
Influenza Market. The increase in the prevalence of influenza in the European
region is a major driving factor for the growth of European Influenza market.
According to EMEA, approximately 15,000 people die of the severe consequence of
influenza. Similarly, change in lifestyle, food habituations, and climatic
conditions in European countries such as Austria, Germany, U.K., Spain, and
Switzerland, among others also increase the growth of Europe Influenza market.
Some of the players in
Europe influenza market are AstraZeneca (U.K.), F. Hoffmann-La Roche
(Switzerland), GlaxoSmithKline Plc. (U.K.), Novartis AG (Switzerland), Sanofi
(France), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.),
BioCryst Pharmaceuticals.Inc. (U.S.), and Abbott Laboratories Inc. (U.S.) to
name a few.
In June 2016, new
four-strain influenza vaccine, Vaxigriptetra, regulatory dossier from Sanofi
Pasteur approved in Europe
Report Outline:
The report provides granular
level information about the market size, regional market share and forecast
from 2017-2023
The report covers
in-detail insights about the competitor’s overview, key findings and their key
strategies
The report outlines
drivers, restraints, challenges, and trends that are currently faced by the
industry
The report tracks recent
innovations, key developments and startup’s details that are working in the
industry
The report provides
plethora of information about market entry strategies, regulatory framework and
reimbursement scenario
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/2753878-europe-influenza-market-market-estimation-dynamics-regional-share-trends-competitor
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive statistical surveying,
market research reports, analysis & forecast data for industries and
governments around the globe.
Contact
Us:
NORAH
TRENT
Ph:
+162-825-80070 (US)
Ph: +44 203
500 2763 (UK)
Comments
Post a Comment